Valeritas’ V-Go® Disposable Insulin Delivery Device Enables Long-Term Care (LTC) Residents Better Glycemic Control with Far Fewer Injections and Decreases Nursing Labor Costs in LTC Settings
Data from a recent retrospective analysis presented in a poster at the ASCP Meeting in Long Beach, California.
BRIDGEWATER, New Jersey, November 3, 2015 – Valeritas Inc. announced today the results of a retrospective analysis based on the records of five residents of The Meadows Nursing and Rehabilitation Center in Dallas who had switched from insulin injection therapy to the V-Go® Disposable Insulin Delivery device. The results of the study were presented at the American Society of Consultant Pharmacists (ASCP) meeting in Long Beach, California this past weekend in a poster titled IMPROVED GLYCEMIC CONTROL AND REDUCED GLUCOSE EXCURSIONS WITH THE V-GO® INSULIN DELIVERY DEVICE IN THE LONG-TERM CARE SETTING. The poster was authored by Jerry Sauter, PharmD, Alan Boonin, MD, Brenda Balinski, RN, Scott Abbott, MS, and Joe Martinez, RPh, PDE, PPC.
V-Go is a simple, wearable, basal-bolus insulin delivery solution for patients with diabetes that enables patients to administer a continuous, preset basal rate of insulin over 24 hours and provides on-demand bolus dosing at mealtimes with U-100 fast-acting insulin. V-Go is available in basal rates of 20, 30 or 40 units and can administer up to an additional 36 units of insulin for mealtime bolus dosing in 2-unit increments, allowing for a total daily of dose of 56, 66 or 76 units/day.
In this retrospective analysis, blood glucose levels (SD) reduced from 204.0 mg/dl (87.7) pre-V-Go to 163.5mg/dl (65.8) during V-Go therapy (p<0.001). Blood glucose Time in Range (100-200mg/dl) during V-Go therapy increased to 59.8% from 42.2% pre-V-Go. And, glucose excursions >200mg/dl reduced by 48%. There were no reports of hypoglycemic events below 50mg/dl. The number of unique daily injections decreased from a pre-V-Go average of 5.25 to 1 application of V-Go. The calculated mean A1C reduction went from 8.7% to 7.3%. From a financial perspective, transitioning these long-term care residents to V-Go produced a nursing and labor time savings of 26.3 minutes per day per patient with a projected cost savings of $26,185 per year per five patients.
“There is an ongoing challenge to help residents in long-term care facilities control their blood glucose levels. In this retrospective study, the investigators sought to learn if switching these patients from other insulin injection therapies to V-Go would make a measurable difference in delivering and simplifying insulin therapy. Data suggests favorable changes in glycemic control. In addition, the healthcare team was able to administer insulin using fewer injections leading to significantly reduced nursing and labor costs,” said John Timberlake, President and CCO at Valeritas. “This analysis shows early promising results on the value of V-Go in the long-term care setting.”
To receive a copy of this poster, please contact, [email protected].
About the V-Go® Disposable Insulin Delivery Device
V-Go® is a small, discreet, wearable and easy-to-use disposable insulin delivery solution for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24–hour period and also providing for on-demand bolus dosing at mealtimes. V-Go is mechanical and operates for 24 hours without electronics or batteries. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick.
Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, V-Go® is the first, simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous, preset basal rate of insulin over 24 hours. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D; functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Press Contact:
Marjie Hadad
MH Communications
[email protected]
908-947-0378